|
|
Article: Bristol-Myers Squibb's Quinolone Antibiotic TEQUIN(TM) (gatifloxacin) Passes Half-Million Mark in New U.S. Prescriptions.
- Article from:
- PR Newswire
- Article date:
- August 1, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TEQUIN Sets New Quinolone Six-Month Prescription Record Previously
Set By Levaquin(R) (levofloxacin)
PRINCETON, N.J., Aug. 1 /PRNewswire/ --
Bristol-Myers Squibb Company (NYSE: BMY) announced that TEQUIN, a quinolone antibiotic, has been prescribed for more than 500,000 patients in the United States since the product was approved by the U.S. Food and Drug Administration on December 17, 1999. TEQUIN is the first quinolone antibiotic to achieve this milestone during the first six months on the market, according to audited data (June, 2000) from IMS Ltd. Prior to the introduction of TEQUIN, the six-month new prescription record for quinolones was ...